Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes

Leukemia Research

Volumn 30, Issue 9, 2006, Pages 1097-1104

  Walters, Denise K ^a   Goss, Valerie L ^b   Stoffregen, Eric P ^a   Gu, Ting Lei ^b   Lee, Kimberly ^b   Nardone, Julie ^b   McGreevey, Laura ^a   Heinrich, Michael C ^a   Deininger, Michael W ^a   Polakiewicz, Roberto ^b   Druker, Brian J ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

AML; Leukemia; Phosphopeptide; Tyrosine kinases

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN; JANUS KINASE 2; PHOSPHOPROTEIN; PROTEIN TEL ARG; SMALL INTERFERING RNA; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DOWN REGULATION; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS;

CARCINOGENS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MASS SPECTROMETRY; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS;

EID: 33745717815     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.01.001     Document Type: Article

References (26)

1. Birkenkamp K.U., Geugien M., Lemmink H.H., et al. Regulation of constitutive STAT5 phosphorylation in acute myelogenous leukemia blasts. Leukemia 15 (2001) 1923-1931
2. Hayakawa F., Towatari M., Iida H., et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol 101 (1998) 521-528
3. Rane S.G., and Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 19 (2000) 5662-5679
4. Spiekermann K., Dirschinger R.J., Schwab R., et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 101 (2003) 1494-1504
5. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 (2005) 721-724
6. Goemans B.F., Zwaan C., Miller M., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19 (2005) 1536-1542
7. O'Farrell A.M., Foran J.M., Fiedler W., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
8. Rush J., Moritz A., Lee K.A., et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23 (2005) 94-101
9. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
10. Walters D.K., Stoffregen E.P., Heinrich M.C., et al. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 105 (2005) 2952-2954
11. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
12. Okuda K., Weisberg E., Gilliland D.G., et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 97 (2001) 2440-2448
13. Flores-Morales A., Pircher T.J., Silvennoinen O., et al. In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2. Mol Cell Endocrinol 138 (1998) 1-10
14. Fujitani Y., Hibi M., Fukada T., et al. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 14 (1997) 751-761
15. Levine R.L., Loriaux M., Huntly B.J.P., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood (2005) (Epub ahead of print)
16. Robinson D.R., Wu Y.M., and Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 19 (2000) 5548-5557
17. Shuai K., Halpern J., ten Hoeve J., et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukaemia. Oncogene 13 (1996) 247-254
18. Okuda K., Sato Y., Sonoda Y., et al. The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. Int J Hematol 79 (2004) 138-146
19. Kishi K., Toba K., Azegami T., et al. Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17). Exp Hematol 26 (1998) 135-142
20. Andersson B.S., Bergerheim U.S., Collins V.P., et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol 20 (1992) 361-367
21. Kurzer J.H., Argetsinger L.S., Zhou Y.J., et al. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bß. Mol Cell Biol 24 (2004) 4557-4570
22. Feener E.P., Rosario F., Dunn S.L., et al. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 24 (2004) 4968-4978
23. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
24. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
25. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 (2005) 22788-22792
26. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) (Epub ahead of print)